Learn how long you'll likely receive Keytruda infusions, what factors can affect your treatment length, and what to expect ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Merck's Keytruda (pembrolizumab) has hit the mark in the late-stage NRG-GY018 trial, with a combination of the drug plus chemotherapy improving progression-free survival (PFS) versus chemo alone ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The product is supplied as a single-dose vial containing 1mg of glucagon per 0.2mL. In an open-label single-dose study, the safety of Gvoke VialDx 0.75mg as a diagnostic agent was evaluated in 83 ...

Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...